What Revisions to the Declaration of Helsinki Mean to Healthcare Marketers

By day I work with study sponsors on communication around clinical trials to accelerate recruitment and increase retention. Lately, in off hours, I find myself discussing regulations concerning ethical and equitable clinical trials with my son, who is a high school senior taking Bioethics. 

I recently read “A Modernized Set of Ethical Principles to Promote and Ensure Respect for Participants in a Rapidly Innovating Medical Research Ecosystem” by Jack S. Resneck Jr., M.D., which discusses recent updates to the Declaration of Helsinki (DoH). These updates have significant implications for both healthcare marketers and bioethics students, highlighting the evolving ethical landscape of clinical trials. 

Originally published in 1964, the DoH remains a cornerstone for ethical guidelines, particularly in clinical trials, along with Good Clinical Practice, Universal Declaration on Bioethics and Human Rights, among others. Healthcare marketers involved in clinical trials need to understand the recent updates to clearly communicate ethical research practices and maintain public trust.  

Here is a synopsis of the key changes to the 2024 Declaration of Helsinki paraphrased from the Resneck opinion article in the Journal of the American Medical Association (JAMA). 

1. Inclusion of Broader Stakeholders: The updates created over 2.5 years were developed with input from a diverse group of stakeholders, beyond bioethicists and researchers. The updates now include patients from 19 countries to reflect a global and inclusive approach to ethical guidelines. 

2. Data Privacy and Consent: The group noted inadequate reference in the current guidelines to consent requirements and participant protections for the increasing use of personal data from trials, particularly concerning use of machine learning and genetic data. Ethics committees must approve and monitor data use, even for secondary research. The updated language requires free and informed consent for collecting, processing, storing, and using biological material and data foreseeably.  

3. Language Shift: One significant update is the replacement of the term "subjects” with "participants." This change is not merely semantic. It reflects a broader cultural shift toward recognizing participants as both human and active collaborators in research. The update also calls for “meaningful engagement with potential and enrolled participants and their communities.” 

4. Inclusive Ethical Principles: Ethical standards now apply to all individuals, teams and organizations involved in medical research, not just physicians, ensuring a uniform ethical approach across research teams. 

5. Addressing Vulnerability and Justice: The revised DoH advocates for the inclusion of historically marginalized and underrepresented groups in research and stresses the fair distribution of research benefits and risks. 

6. Public Health Emergencies: Ethical principles must be upheld even during emergencies, as demonstrated by the COVID-19 pandemic. The revisions caution against using emergencies as an excuse to bypass established ethical standards, ensuring that urgency does not compromise participant safety and rights. 

7. Sustainability and Scientific Integrity: The doctrine now emphasizes environmentally sustainable practices, rigorous research design to prevent waste, and centering scientific integrity. 

8. Strengthen Ethics Committees: The DoH now insists on sufficient resources for ethics committees and strengthens their independence. This move is aimed at bolstering the capacity of these committees to oversee research practices and ensure compliance with ethical standards. 

Implications for Healthcare Marketers  

The 2024 updates to the DoH provide healthcare marketers with an opportunity to highlight the ethical foundations of clinical research. By incorporating these changes into communication strategies, marketers can contribute to a research environment that prioritizes participant rights and protection. For the pharmaceutical industry, adhering to ethical practices is important for maintaining public trust and credibility. Following the DoH is a way for the industry to demonstrate its commitment to ethical standards, ensuring that research is conducted transparently, responsibly, and respectfully. 

These updates allow marketers to promote ethical research practices, highlighting their significance to both the public and healthcare professionals. By demonstrating adherence to these practices, marketers can build trust and encourage support for clinical trial participation. 

Moreover, healthcare marketers have a crucial role in promoting inclusivity and diversity within clinical trials. For too long, clinical research has not included many people who could most benefit from life-saving medicines. By ensuring that diverse populations who will ultimately take the medicines are represented, we can help address and overcome barriers to participation, ultimately contributing to more equitable and comprehensive research outcomes. 

Here are some of the ways we recommend our clients educate patients and their healthcare providers and work with communities to help overcome barriers to participation in clinical trials: 

• First, emphasize personalized engagement strategies, avoiding one-size-fits-all approaches and, instead, develop tailored strategies that resonate with participants based on their unique cultural, social, and economic contexts. This targeted approach enhances recruitment and retention rates and fosters deeper trust and collaboration with underserved populations. 

• Engage with Community Serving Organizations (CSOs) with a strong presence and influence within the target community and align with goals and objectives. Partner with different community groups to learn behaviors, motivations, biases, and fears while building long-term relationships on a foundation of authentic trust.​  

• Reach diverse, trial-eligible patients through the physicians they trust to promote health literacy and disease/trial education and emphasize the focus on ensuring free and informed consent for collecting, processing, storing, and using biological material and data. 

• Consider heightened awareness of the myriad reasons for mistrust – from Tuskegee to Henrietta Lacks – when developing recruiting messaging. Be sure the content you develop is focused on cultural humility to support target healthcare providers in understanding and addressing the very real barriers to trust in the medical community. Help inform historically underrepresented patients about the importance of clinical trial participation, including the fair distribution of research benefits and risks. 

Learn more about Real Trial Solutions and contact us to discover how our integrated services can speed up your trial recruitment and deliver measurable results. Email newbizteam@realchemistry.com to learn more. Let's make a real difference together.